Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC. (VNDA)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:50pm CEST

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; [email protected]

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 0.04% 82.71 Delayed Quote.-2.11%
VANDA PHARMACEUTICALS INC. 1.78% 17.2 Delayed Quote.13.16%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
05/23VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
05/17VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 43rd Annual Health Care ..
AQ
05/08VANDA PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
AQ
05/07VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 43rd Annual Health Care ..
PR
05/02VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
05/02VANDA : 1Q Earnings Snapshot
AQ
05/02VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
AQ
05/02VANDA PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
PR
04/25VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K..
AQ
04/25VANDA PHARMACEUTICALS : to Announce First Quarter 2018 Financial Results on May ..
AQ
More news
News from SeekingAlpha
05/23Vanda's Hetlioz effective in jet lag study 
05/23Premarket analyst action - healthcare 
05/10Vanda Pharmaceuticals (VNDA) Presents At 43rd annual Deutsche Bank Healthcare.. 
05/03HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (05/03/2018) 
05/02Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results - .. 
Financials ($)
Sales 2018 192 M
EBIT 2018 -40,7 M
Net income 2018 -16,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 49,61
Capi. / Sales 2018 4,67x
Capi. / Sales 2019 3,84x
Capitalization 896 M
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,7 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Secretary & Treasurer
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.13.16%896
GILEAD SCIENCES-5.60%87 807
VERTEX PHARMACEUTICALS4.75%40 001
REGENERON PHARMACEUTICALS-21.45%31 214
GENMAB19.78%11 741
BEIGENE LTD (ADR)97.99%10 063